cancer doctors

Melanoma Cancer Prognosis

Question: Does Squamous Cancer lead to melanoma? Once squamous cancer cells have been found, what is the correct follow up and prognosis? The area was removed, but how soon should I have a follow up? What are things I should look for?

Answer: Squamous cell does not lead to melanoma because squamous is a completely different type of cell and skin cancer. You can have both types of skin cancer but not in the same exact spot. Followup should be in six months if you don't have any other suspicious skin lesions and once a year after this original follow up. If the squamous cell was removed recently, watch the area closely for new redness or if the wound quits healing return to your dermatologist. Often in the area where a squamous has been removed the Dr will cauterize the skin which may look bad for a while but is not the same as a recurrence. A recurrence might happen 3-6 months or more after the original squamous was removed. If a dermatologist removed the original squamous and the squamous wasn't real large then you probably don't have anything to worry about from this same spot as the cure rate is quite high. You do need to always use a strong broad spectrum suntan lotion on this area from now on, no exceptions. Also, after you have had one squamous your chances for another squamous and all skin cancers in general is now significantly higher than in someone who has never had a skin cancer removed. http://www.nlm.nih.gov/medlineplus/ency/…


Melanoma Cancer Prognosis News

Melanoma Drug Resistance Linked to Kinase Control of Transcription Factor Activity

Genetic Engineering News
Describing their work in cultured cells, Sanford-Burnham's Ze'ev A. Ronai , Ph.D., and colleagues subsequently confirmed that in primary human melanoma, high levels of PKC? are associated the most with aggressive tumors and poorer patient survival.
 

Pfenninger: A summary of malignant melanoma

Midland Daily News
The word "melanoma" strikes a chord of fear in all of us when we hear it. It should. It is a skin cancer which forms in the pigment-producing cells of the skin. Found early, when it is less than a millimeter deep, there is a good prognosis.
 

Scientists find molecular switch that allows melanoma to resist therapy

Medical Xpress
To do this, Ronai's laboratory has been studying a protein named Activating Transcription Factor 2 (ATF2), which is associated with poor prognosis in melanoma. ATF2 is a two-faced protein?in melanoma cells, it's oncogenic, or cancer-causing, ...
 

The skin cancer you're not looking for

Fox News
This matters, because a cancer's depth can determine the chances of survival. "One of the most important aspects of prognosis is how deep the melanoma is when it's found," said Dr. Roy Grekin, professor of dermatology and director of the dermatologic ...
 

Trends in Melanoma Mortality Among Non-Hispanic Whites by Educational ...

Archives of Dermatology
4 Studies have suggested that socioeconomic status (SES) factors may influence melanoma survival and related prognostic factors, including advanced stage, tumor thickness, and case-fatality rates. 1, 5-10 Early recognition of melanoma is the ...
 

BioAlliance Pharma Announces Two Key Steps with Its AMEP(TM) Biotherapy for ...

MarketWatch (press release)
The metastatic melanoma in an invasive skin cancer of bad prognosis. Its strong therapeutic need is still unmet. World Health Organization (WHO) estimates that worldwide there are nearly 200000 new cases of melanoma and more than 46000 deaths annually ...
 

Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2012

MarketWatch (press release)
ARRY-520-induced apoptosis requires loss of the survival protein MCL-1. Myeloma and other hematologic cancers depend on MCL-1 as a key survival protein. ARRY-520 has demonstrated durable single-agent activity in patients with dual-refractory MM, ...
 

Nature.com

2011 FDA drug approvals
Nature.com
 

New Shots at Treating Breast Cancer

dailyRx
?Basically, we'll push it over a cliff because those pathways are critical for tumor survival.? "This is an interesting study of a potential new strategy for treating DCIS," Adam Brufsky, MD, Ph.D., professor of medicine at the University of Pittsburgh ...
 

Biotech Stock Mailbag: Vical, Hep C Drugs

TheStreet.com
Comparable studies of other melanoma drugs, most notably Bristol-Myers Squibb's(BMY) recently approved Yervoy, enrolled significantly more patients with prognostic factors such as these that makes tumor response and survival endpoints harder to achieve ...
 

Types of Cancer


Adrenal Cancer Anal Cancer Brain Cancer Colorectal Cancer Endometrial Cancer Esophageal Cancer
Esophageal Cancer Laryngeal Cancer Oral Cancer Penile Cancer Prostatic Cancer Stomach Cancer
Thyroid Cancer Bladder Cancer Bone Cancer Cervix Cancer Heart Cancer Kidney Cancer
Melanoma Cancer Pancreas Cancer Asbestos Cancer